ApplicationAs p53 mutations associate with undifferentiated carcinoma but not well differentiated carcinoma during multistep carcinogenesis of the thyroid, these cell lines should prove useful for research into the role of gene mutation in malignant transformation.
Biochem/physiol ActionsEstablished from undifferentiated thyroid carcinomas of a 67 year old female patient. Pathologically the carcinoma tissue contained residual well differentiated components suggesting well differentiated to undifferentiated carcinoma progression. Tumour suppresser genes p53, Rb, APC and MCC were analysed and sequence analysis confirmed a C:G to T:A transition at the first base of p53 gene codon 273. Loss of heterozygosity of tumour suppresser genes was not observed.
Human thyroid anaplastic carcinoma, undifferentiated.
STR-PCR Data: Amelogenin: X
CSF1PO: 9,12
D13S317: 9
D16S539: 10,11
D5S818: 10,13
D7S820: 8,10
THO1: 6,7
TPOX: 8
vWA: 14,16
Preparation NoteEMEM (HBSS) + 2mM Glutamine + 1% Non Essential Amino Acids (NEAA) + 10% Foetal Bovine Serum (FBS).
Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4 x 10,000 cells/cm² using 0.25% trypsin/EDTA; 5% CO₂; 37°C. Doubling time is 43 hours. Saturation density at confluency is 5.7x10,000 cells/cm².
Other NotesAdditional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to
[email protected].
